SEC Company Response from RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636) — Oct 26, 2020

RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636)
Date: Oct. 26, 2020 · CIK: 0000849636 · Accession: 0001493152-20-019956

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-249469

Date

Oct. 26, 2020

Author

RESPIRERX

Form

CORRESP

Company

RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636)

Letter

VIA EDGAR Division of Corporation Finance Washington, D.C. 20549 Re: RespireRx Pharmaceuticals Inc. Registration Statement on Form S-1 File No. 333-249469

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), RespireRx Pharmaceuticals Inc. (the “Company”) hereby requests acceleration of the effective date and time of the above-referenced registration statement (the “Registration Statement”) to October 28, 2020, at 5:00 p.m. Eastern Time or as soon thereafter as is practicable. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please inform our counsel, Faegre Drinker Biddle & Reath LLP, by calling Elizabeth A. Diffley at (215) 988-2607.

Sincerely,
RESPIRERX
PHARMACEUTICALS INC.

Show Raw Text

CORRESP
1
filename1.htm

RESPIRERX
PHARMACEUTICALS Inc.

126
Valley Road, Suite C

Glen
Rock, New Jersey 07452

(201)
444-4947

VIA
EDGAR

October
26, 2020

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    RespireRx
    Pharmaceuticals Inc.

    Registration
    Statement on Form S-1

    File
    No. 333-249469

Dear
Ladies and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Act”), RespireRx Pharmaceuticals Inc. (the “Company”)
hereby requests acceleration of the effective date and time of the above-referenced registration statement (the “Registration
Statement”) to October 28, 2020, at 5:00 p.m. Eastern Time or as soon thereafter as is practicable. In making this acceleration
request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once
the Registration Statement is effective, please inform our counsel, Faegre Drinker Biddle & Reath LLP, by calling Elizabeth
A. Diffley at (215) 988-2607.

    Sincerely,

    RESPIRERX
    PHARMACEUTICALS INC.

    By:
    /s/ Jeff E. Margolis

    Jeff
    E. Margolis

    SVP,
    CFO, Secretary and Treasurer

cc:
Elizabeth A. Diffley

Faegre
Drinker Biddle & Reath LLP

SecProbe.io